The Claim
In obese adults, administration of trimetazidine at 35 mg/day for one month increases the rate constant of fatty acid esterification in skeletal muscle by approximately 10% and produces a borderline increase in glucose phosphorylation, indicating a metabolic shift from fat oxidation toward fat storage and glucose utilization.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese adults, taking trimetazidine 35 mg daily for one month increases the rate at which fatty acids are stored as fat in muscle tissue and slightly increases glucose processing, indicating a change in how muscle uses energy.
See the scientific wording
In obese adults, trimetazidine (35 mg/day for one month) increases the rate constant of fatty acid esterification in skeletal muscle by approximately 10% and shows a borderline increase in glucose phosphorylation, suggesting a shift in muscle metabolism from fat oxidation toward fat storage and glucose utilization.
Trimetazidine blocks a key enzyme in the fat-burning pathway inside muscle cells, causing fatty acids to build up instead of being burned for energy. These extra fatty acids get stored as fat inside the muscle, and the muscle starts using more sugar for fuel because it can't rely on fat as much anymore.
What the research says
1 studyThe study found that taking trimetazidine for a month helped muscle cells store fat instead of burning it, and slightly improved how they use sugar — just like the claim said, though the sugar effect wasn’t strong enough to be certain.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.